We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fecal Immunochemical Test a Less Expensive Alternative for Colorectal Cancer Screening

By LabMedica International staff writers
Posted on 18 Oct 2022
Print article
Image: FIT has been found to detect early-stage cancer at one-fifth the cost (Photo courtesy of Allegheny Health)
Image: FIT has been found to detect early-stage cancer at one-fifth the cost (Photo courtesy of Allegheny Health)

Guidelines issued by the U.S. Preventive Services Task Force (USPSTF) suggest a fecal immunochemical test (FIT) can be used as the primary noninvasive screening modality for early-stage colorectal cancer, although a significant proportion of patients still receive a more expensive alternative test called Cologuard. Commercially available noninvasive screening tests for colorectal cancer - a FIT and the multi-target stool DNA test (mt-sDNA; or Cologuard) - are equally effective for screening patients with early-stage colorectal cancer. Data used for national screening guidelines has shown no difference between the two tests at detecting adenoma versus colorectal malignancy. However, a new study has revealed that a FIT costs about one-fifth of the multi-target DNA test. These results align with previous studies out of Japan and the Netherlands examining FIT as an appropriate screening modality that is more cost effective than other types of noninvasive colorectal screening tests.

In the study, researchers at Allegheny Health Network (Pittsburgh, PA, USA) looked at 117,519 people in the Highmark claims database who underwent colorectal screening in 2019. Highmark is a Blue Cross Blue Shield Association insurer in four Mid-Atlantic states. From that group, the researchers identified 91,297 people who had noninvasive screening with either the fecal immunochemical test (FIT, n=45,487) or the DNA test (mt-sDNA, n=46,110) instead of having a routine colonoscopy. The findings revealed that among the study population that underwent colorectal screening, 45,487 (38.7%) had one of two commercially available FIT tests and 46,110 (39.2%) had the mt-sDNA test. Patients who were screened with either test presented with early disease, staged from 0 to II, at similar rates: 59.5% for FIT and 63.2% for mt-sDNA test (p=0.77).

Patients within the Allegheny Health Network Oncology Registry diagnosed with colorectal cancer were matched to their claims data to determine distribution of cancer stage. If the noninvasive test indicated signs of early disease, patients were then referred for additional testing to confirm the findings. The total annual costs for the tests were USD 6.47 million - USD 1.1 million for a FIT, or about USD 24 per test, and USD 5.6 million for mt-sDNA, or about USD 121 per test. Costs were calculated using Medicare reimbursement rates. The researchers determined that transitioning all noninvasive colorectal cancer screening to FIT would result in a USD 3.9 million savings annually in the study population. What makes this study unique is the methodology used to analyze the claims data. The researchers analyzed outcomes in the local health registry and then applied those outcomes to the claims database. The cost of a screening colonoscopy in the database the researchers used was USD 635.

"Despite national guidelines suggesting that FIT be used as the primary noninvasive screening modality, we found that on review of our insurer's claims data, a significant proportion of patients still receive a more expensive alternative test. There is substantial cost savings not only to our patients but to our health system with promoting appropriate use of noninvasive testing," said Pavan K. Rao, MD, a general surgery resident at Allegheny Health Network. "There was no difference in the clinical stage at the time of diagnosis between the two tests, which again demonstrates the clinical equipoise maintained by switching to FIT."

"It's not just the cost of the mt-sDNA test kit or the cost of the FIT kit multiplied by the number of members in the healthcare system," said study coauthor Casey J. Allen, MD, a surgical oncologist at Allegheny Health Network. "It's the full downstream costs depending on the rates of false-positive and false-negative tests and how much it costs to obtain a colonoscopy when that occurs."

Related Links:
Allegheny Health Network 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.